Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone (PVd) demonstrated superior efficacy vs bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma previously treated with lenalidomide, including those refractory to lenalidomide. This analys...

Descripción completa

Detalles Bibliográficos
Autores: Dimopoulos, M.A. (Meletios A.)|||/items/15a77e11-69c3-44a2-8476-eb93bbe8cc0e, Weisel, K. (Katja)|||/items/2b91c472-77fe-41ac-888c-5b2e0c5d7197, Moreau, P. (Philippe)|||/items/3d8d9f42-9629-4e12-9854-43031d9b6332, Sin Autoridad|||/items/5ef2b52f-de1a-4ddf-9648-596a6dd222b4, White, D.J. (Darrell J.)|||/items/12ed8431-705b-40ea-9bd1-a77ab01f964d, San-Miguel, J.F. (Jesús F.)|||/items/114f598d-f226-4fa6-aa75-909241328543, Sonneveld, P. (Pieter)|||/items/24063b12-1f63-4151-b5b3-36d4a255dbc8, Engelhardt, M. (Monika)|||/items/19022ea7-5d61-41b2-8552-38296d8afb2c, Dürig, J. (Jan)|||/items/26998797-f9a7-4609-a0e7-45a958633fbc, Nguyen, V. (V.)|||/items/0b74d56e-8cb6-4dc5-b926-451ae02018ea, Richardson, P.G. (Paul G.)|||/items/4a03f76e-f4e1-4490-8091-a79e8ea86861
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/115299
Acceso en línea:https://hdl.handle.net/10171/115299
Access Level:acceso abierto
Palabra clave:Pomalidomide
Bortezomib
Dexamethasone
Descripción
Sumario:In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone (PVd) demonstrated superior efficacy vs bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma previously treated with lenalidomide, including those refractory to lenalidomide. This analysis evaluated outcomes in patients at first relapse (N = 226) by lenalidomide-refractory status, prior bortezomib exposure, and prior stem cell transplant (SCT). Second-line PVd significantly improved PFS vs Vd in lenalidomide-refractory (17.8 vs 9.5 months; P = 0.0276) and lenalidomide-nonrefractory patients (22.0 vs 12.0 months; P = 0.0491), patients with prior bortezomib (17.8 vs 12.0 months; P = 0.0068), and patients with (22.0 vs 13.8 months; P = 0.0241) or without (16.5 vs 9.5 months; P = 0.0454) prior SCT. In patients without prior bortezomib, median PFS was 20.7 vs 9.5 months (P = 0.1055). Significant improvement in overall response rate was also observed with PVd vs Vd in lenalidomide-refractory (85.9% vs 50.8%; P < 0.001) and lenalidomide-nonrefractory (95.7% vs 60.0%; P < 0.001) patients, with similar results regardless of prior bortezomib or SCT. No new safety signals were observed. These data demonstrate the benefit of PVd at first relapse, including immediately after upfront lenalidomide treatment failure and other common first-line treatments.

Similares en LA Referencia